Skip to search formSkip to main contentSkip to account menu

elesclomol

Known as: 1-N'-benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl- oxopropanehydrazidide, Propanedioic Acid, Bis[2-methyl-2-(phenylthioxomethyl)hydrazide] 
A small-molecule bis(thio-hydrazide amide) with oxidative stress induction, pro-apoptotic, and potential antineoplastic activities. Elesclomol… 
National Institutes of Health

Related topics

Related topics

4 relations
Elesclomol SodiumNCIt Antineoplastic Agent Terminology

Broader (1)

Hydrazines

Narrower (1)

STA-4783

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Elesclomol rescues Menkes disease mice
Biomedicine Menkes disease results from loss-of-function mutations in the P-type copper-transporting adenosine triphosphatase… 
2018
2018
Abstract 4846: TargetingBRCA1-mutated cancer cells with elesclomol
The breast cancer susceptibility gene 1 (BRCA1) encodes a tumor-suppressor protein that maintains genetic stability through DNA… 
2016
2016
Abstract 278: No cell left behind: Residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol
Sphere forming cells persist in the ascitic fluid of patients with high-grade serous ovarian cancer after first-line therapy and… 
2014
2014
12 Next generation sequencing (NGS) guided therapy prediction for the treatment of glioblastoma multiforme (GBM)
2012
2012
Abstract 1761: Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol-induced oxidative DNA damage
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Hereditary breast cancers due to germline… 
2010
2010
Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update.
8550^ Background: Elesclomol is an investigational first-in-class oxidative stress inducer that increases reactive oxygen species… 
2009
2009
Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM).
LBA9012 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings… 
2008
2008
Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapy
9036 Background: Elesclomol is a novel small-molecule oxidative stress inducer known to synergize with taxanes and certain other… 
2008
2008
Integrated safety analysis of elesclomol (formerly STA-4783) co-administered with paclitaxel
14595 Background: Elesclomol is a novel small-molecule oxidative stress inducer known to synergize with taxanes and certain other… 
2008
2008
Elesclomol (formerly STA-4783) induces oxidative stress selectively in cancer cells and inhibits tumor growth independent of immune status
3300 Background: Elesclomol (formerly STA-4783) is a novel, small molecule investigational drug candidate that stimulates… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)